1. Hornby, P. J. Central neurocircuitry associated with emesis. Am J Med 2001; 111(suppl 8A): 106S-12S.
2. Mannix, K. Palliation of nausea and vomiting. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 490-8.
3. Rousseau, P. Non-pain symptom management in terminal care. Clin Geriatr Med 1996; 12: 313-6.
4. Hesketh, P. J. et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ- 11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17(1): 338-43.
5. Hesketh, P. J. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001; 9(5): 350-4.
6. Twycross, R. Pain Relief in Advanced Cancer. 1994, Churchill Livingstone: London.
7. Malik, I. A. et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995; 18(2): 170-5.
8. Priestman, T. J. et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2(2): 71-5.
9. Priestman, T. J., J. T. Roberts, et al. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 1993; 5(6): 358-63.
10. Roberts, J.T. and T.J. Priestman. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 1993; 50(3): 173-9.
11. Diemunsch, P. and L. Grelot. Potential of substance P antagonists as antiemetics. Drugs 2000; 60(3): 533-46.
12. Peroutka, S. J. and S. H. Snyder. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1(8273): 658-9.
13. Terndrup, T. E. et al. Comparison of intramuscular meperidine and promethazine with and without chlorpromazine: A randomized, prospective, double-blind trial. Ann Emerg Med 1993; 22(2): 206-11.
14. Ernst, A. A. et al. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: A randomized, double-blind clinical trial. Ann Emerg Med 2000; 36(2): 89-94.
15. Bruera, E. and et al. Chronic nausea in advanced cancer patients: A retrospective assessment of metoclopramide-based anti-emetic regimen. J Pain Symptom Manage 1996; 11: 147-53.
16. Loewen, P. S., C. A. Marra, et al. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth 2000; 47(10): 1008-18.
17. Hoskin, P. Radiotherapy in symptom management. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 267-82.
18. Kast, R. E. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9(6): 469-70.
19. Tramer, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 2001; 323(7303): 16-21.
20. Hallenbeck, J. and D. E. Weissman. Fast Fact and Concept #5: Treatment of nausea and vomiting. End of Life Education Project. http://www.eperc.mcw.edu/, 2000.
21. Enck, R. The Medical Care of Terminally Ill Patients. 1994, Johns Hopkins University Press: Baltimore, pp. 28-32.
22. Mancini, I. and E. Bruera. Constipation in advanced cancer patients. Support Care Cancer 1998; 6(4): 356-64.
23. Bruera, E. et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective review. J Pain Symptom Manage 1994; 9(8): 515-9.
24. Hallenbeck, J. and D. E. Weissman. Fast Fact and Concept #15; Constipation. End of Life Education Project. http://www.eperc.mcw.edu/, 2000.
25. Fallon, M. and B. O'Neill. ABC of palliative care. Constipation and diarrhoea. BMJ 1997; 315(7118): 1293-6.
26. Ahmedzai, S. and D. Brooks. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fetanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254-61.
27. Radbruch, L. et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-9.
28. Hunt, R. et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manag 1999; 18: 111-9.
29. Hurdon, V., R. Viola, et al. How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. J Pain Symptom Manage 2000; 19(2): 130-6.
30. Ripamonti, C. et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9(4): 223-33.
31. Beattie, G., F. Leonard, et al. Bowel obstruction in ovarian carcinoma: A retrospective study and review of the literature. Palliat Med 1981; 3: 275-80.
32. Baines, M., D. Oliver, et al. Medical management of intestinal obstruction in patients with advanced malignant disease: A clinical and pathologic study. Lancet 1985; ii: 990-3.
33. Welch, J. Bowel Obstruction. 1990, WB Saunders: Philadelphia.
34. Hutchison, S., G. Beattie, et al. Increased serotonin excretion in patients with ovarian carcinoma of the ovary. Palliat Med 1995; 9: 67-8.
35. Cubeddu, L. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 1996; 53(suppl 1): 18-25.
36. Isbister, W., P. Elder, et al. Non-operative management of malignant intestinal obstruction. Journal of the Royal College of Physicians of Edinburgh 1990; 35: 369-72.
37. Ventafridda, V. et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990; 76: 389-93.
38. Aranha, G., F. Folk, et al. Surgical palliation of small bowel obstruction due to metastatic carcinoma. Am Surg 1981; 13: 44-9.
39. Krebs, H. and D. Goplerud. The role of intestinal intubation in obstruction of the small intestine due to carcinoma of the ovary. Surgery, Gynecology, and Obstetrics 1984; 158: 467-71.
40. Bizar, L. et al. Small bowel obstruction. Surgery 1981; 89: 407-13.
41. Osteen, R. et al. Malignant intestinal obstruction. Surgery 1980; 67: 611-5.
42. De Conno, F. et al. Continuous subcutaneous infusion of hyscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991; 6: 484-6.
43. Hardy, J. et al. Pitfalls in placebo-controlled trials in palliative care: Dexamethasone for the palliation of malignant bowel obstruction. Palliat Med 1998; 9: 67-8.
44. Tuna, J., D. Buchler, et al. The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol 1981; 12: 186-92.
45. Soetikno, R., D. Lichtenstein, et al. Palliation of malginant gastric outlet obstruction using an endoscopically placed wallstent. Gastrointest Endosc 1998; 12: 267-70.
46. Friedland, S., J. Hallenbeck, et al. Stenting the sigmoid colon in a terminally ill patient with prostate cancer. Journal of Palliative Medicine 2001; 4(2): 153-6.
47. Mangli, G., M. Franchi, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996; 61: 345-8.
48. Khoo, D., E. Hall, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30: 28-30.
49. Mercadante, S. et al. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000; 8(3): 188-91.
50. Ripamonti, C. et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 2000; 19(1): 23-289.
51. Fainsinger, R. et al. Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage 1994; 9: 12-8.
52. Feinle, C. and N. Read. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 271: 6591-7.
53. Ventafridda, V. et al. Mouth care. In: D. Doyle, G. Hanks, et al., eds. The Oxford Textbook of Palliative Medicine. 1998, Oxford University Press: New York, pp. 691-8.
54. Ng, K. and C. F. von Gunten. Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. J Pain Symptom Manage 1998; 16(5): 307-16.
55. McCann, R. M., W. J. Hall, et al. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272(16): 1263-6.
56. Stern, L. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997; 33: 52-4.
57. Olsen, A. K. and P. Sjogren. Oral glycopyrrolate alleviates drooling in a patient with tongue cancer. J Pain Symptom Manage 1999; 18: 300-2.
58. Ripamonti, C. and E. Bruera. Dyspnea: Pathophysiology and assessment. J Pain Symptom Manage 1997; 13(4): 220-32.
59. Reuben, D. B. and V. Mor. Dyspnea in terminally ill cancer patients. Chest 1986; 89(2): 234-6.
60. Bruera, E. et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19(5): 357-62.
61. Skilbeck, J. Palliative care in chronic obstructive airways disease: A needs assessment. Palliat Med 1998; 12: 245-54.
62. Watanabe, S. The role of oxygen in cancer-related dyspnea. In: R. Portenoy and E. Bruera, eds. Topics in Palliative Care. 2000, Oxford University Press: New York, pp. 255-60.
63. Bruera, E. et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342(8862): 13-4.
64. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159(1): 321-40.
65. Cristiano, L. M. and R. M. Schwartzstein. Effect of chest wall vibration on dyspnea during hypercapnia and exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155(5): 1552-9.
66. Edo, H. et al. Effects of chest wall vibration on breathlessness during hypercapnic ventilatory response. J Appl Physiol 1998; 84(5): 1487-91.
67. Nakayama, H. et al. In-phase chest wall vibration decreases dyspnea during arm elevation in chronic obstructive pulmonary disease patients. Intern Med 1998; 37(10): 831-5.
68. Bruera, E. et al. Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage 1990; 5(6): 341-4.
69. Mazzocato, C., T. Buclin, et al. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: A randomized double-blind controlled trial. Ann Oncol 1999; 10(12): 1511-4.
70. Zeppetella, G. Nebulized morphine in the palliation of dyspnoea. Palliat Med 1997; 11: 267-73.
71. Chandler, S. Nebulized opioids to treat dyspnea. American Journal of Hospice & Palliative Care 1999; 16(1): 418-22.
72. Stark, R. D. et al. Effects of small-particle aerosols of local anaesthetic on dyspnoea in patients with respiratory disease. Clin Sci (Colch) 1985; 69(1): 29-36.
73. Libby, D., W. Briscoe, et al. Relief of hypoxia-related bronchoconstriction by breathing 30 percent oxygen. American Review of Respiratory Disease 1981; 123: 171-5.
74. Liss, H. and B. Grant. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. American Review of Respiratory Disease 1988; 137: 1285-8.
75. Brennan, M. F. Uncomplicated starvation versus cancer cachexia. Cancer Res 1977; 37(7 pt 2): 2359-64.
76. Dulloo, A. G., J. Jacquet, et al. Poststarvation hyperphagia and body fat overshooting in humans: A role for feedback signals from lean and fat tissues. Am J Clin Nutr 1997; 65(3): 717-23.
77. Alexander, H. Prevalence and pathophysiology of cancer cachexia. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 91-129.
78. Inui, A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999; 59(18): 4493-501.
79. Dunlop, R. J. and C. W. Campbell. Cytokines and advanced cancer. J Pain Symptom Manage 2000; 20(3): 214-32.
80. Freeman, L. M. and R. Roubenoff. The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52(10): 340-7.
81. Nemechek, P. M., B. Polsky, et al. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000; 75(4): 386-94.
82. Neuenschwander, H. and E. Bruera. Pathophysiology of cancer asthenia. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 171-81.
83. Cleary, J. F. The reversible causes of asthenia in cancer patients. In: R. K. Portenoy and E. Bruera, eds. Topics in Palliative Care. 1998, Oxford University Press: New York, pp. 183-202.
84. Vigano, A., S. Watanabe, et al. Anorexia and cachexia in advanced cancer patients. Cancer Surv 1994; 21: 99-115.
85. De Conno, F. et al. Megestrol acetate for anorexia in patients with far-advanced cancer: A double-blind controlled clinical trial. Eur J Cancer 1998; 34(11): 1705-9.
86. Yanagawa, H. et al. Palliative steroid therapy and serum interleukin-6 levels in a patient with lung cancer. J Pain Symptom Manage 1996; 12(3): 195-8.
87. Beal, J., R. Olson, et al. Dronabinol as treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89.
88. Gleeson, C. Blood transfusion and its benefits in palliative care. Palliat Med 1995; 9(4): 307-13.
<<< Previous [ Go Up ]
Palliative Care Perspectives
James L. Hallenbeck, M.D.
Copyright © 2003 by Oxford University Press, Inc.
The online version of this book is used with permission of the publisher and author on web sites affiliated with the Inter-Institutional Collaborating Network on End-of-life Care (IICN), sponsored by Growth House, Inc.